Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer
about
To Know How a Gene Works, We Need to Redefine It First but then, More Importantly, to Let the Cell Itself Decide How to Transcribe and Process Its RNAsThe RNA Splicing Response to DNA DamageCirculating RNAs as new biomarkers for detecting pancreatic cancerDefective control of pre-messenger RNA splicing in human diseaseLarge-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networksELF5 isoform expression is tissue-specific and significantly altered in cancer.Pan-cancer analysis for studying cancer stage using protein expression dataHow do messenger RNA splicing alterations drive myelodysplasia?Leveraging transcript quantification for fast computation of alternative splicing profiles.ISOexpresso: a web-based platform for isoform-level expression analysis in human cancerFunctional divergence and convergence between the transcript network and gene network in lung adenocarcinoma.Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma.SURVIV for survival analysis of mRNA isoform variation.The prognostic potential of alternative transcript isoforms across human tumors.The incredible complexity of RNA splicing.Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems.Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.The role of alternative splicing in cancer.TSIS: an R package to infer alternative splicing isoform switches for time-series data.From mechanisms to therapy: RNA processing's impact on human genetics.MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression.Depletion of somatic mutations in splicing-associated sequences in cancer genomes.Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools.The effects of alternative splicing on miRNA binding sites in bladder cancer.Serine/arginine rich splicing factor 2 expression and clinic pathological features indicating a prognostic factor in human hepatocellular carcinoma patients.Framework and resource for more than 11,000 gene-transcript-protein-reaction associations in human metabolism.Splice Expression Variation Analysis (SEVA) for Inter-tumor Heterogeneity of Gene Isoform Usage in Cancer.Genome-wide characterization of differential transcript usage in Arabidopsis thaliana.A system for detecting high impact-low frequency mutations in primary tumors and metastases.A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma.Alternative Splicing as a Target for Cancer Treatment.SUPPA2: fast, accurate, and uncertainty-aware differential splicing analysis across multiple conditions.Identification and characterization of host proteins bound to dengue virus 3' UTR reveal an antiviral role for quaking proteins.Splicing dysregulation as a driver of breast cancerDefective transcription elongation in a subset of cancers confers immunotherapy resistanceDietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling
P2860
Q26774954-291A186C-6393-4FC6-89F3-86BE6A15FAEAQ26777046-72B859FC-65E8-457A-9EC5-98B6BD14CD35Q26801191-7957C648-54D2-4127-BA40-1974A00C883FQ28077564-BB0B2B6A-DADB-45C9-B428-268706ACF3E7Q28275692-30CAA9A4-ADCA-4175-8CCD-32B1E6D7C687Q30383247-C24FA8DD-216D-433A-8CF3-BD27A7D1CFD5Q31035525-1429AE09-74AE-4141-87F7-E95932617414Q33640195-332BEC06-4C0A-4B6D-B7A9-773FE323EEABQ35693081-69622BEC-FE8D-45D1-9793-C1B27CE3B5ACQ36103082-8F45477D-8814-4578-8222-2D3CC01B0A79Q36473639-8EBDB3B7-7E2D-4FF1-A9B6-4D76CDD5C73FQ36771977-AD28DFB3-3515-4BB5-917B-103E248D3CB7Q36991152-5F252B5D-5AEF-497B-A1E7-FCC5FECE0EDDQ37000093-B277A6B6-C2D7-4B46-9E0D-BA86CC83506AQ37185523-D65B9B84-A8B0-43F2-AAA5-288396ED724FQ37547135-E3A4BB8A-FAED-49AA-8027-6E5CDF3776D3Q38715405-B9C9FF39-5DA5-4EF7-A915-DE8DA847DDADQ38735423-19186717-5C95-4CF5-9D5D-98E04645A66EQ39341456-342B2666-0AF9-4F8F-8149-67D68BB8E7BFQ42176799-CD8CB67C-57DA-42CF-8437-A02653617455Q42282317-86C2AD64-474E-488A-9995-4006790E30C0Q42696282-D6714BA3-3B4F-4781-91D8-B931E1A487AEQ44013444-7EB06B1C-D8DE-4B6A-8E3F-37AB452B30FBQ46312463-0A7EF736-611C-472B-A645-7DB7EA59CA6EQ46430064-4F585FDC-13B1-4C29-A67B-63DB048BDB02Q47110708-A57A9197-2E49-4988-BF72-5F6A3B90414CQ47232846-A40028F4-6776-451A-9058-5D93C50592C2Q47253622-F5F81648-F327-4D45-98BA-BCAD777A26E2Q47403037-C4C9D72F-CB61-4359-B1FE-9163F97B4C71Q47561950-09FB3C34-D6F4-4606-8429-A994FE9B73B1Q47654216-C2C1B827-49A9-4DB8-B34E-47335B949FA3Q48095098-76ED4257-172C-4503-ABE7-EDB536C576DAQ49960144-8B27A1F0-7135-4B1F-B6A7-6D39FBC790E3Q50033988-953D1735-1CD5-4BB7-A372-59F5A461149FQ52640042-7A57E010-27C8-44F4-9F38-B10F0B52E966Q54249620-F1FBE694-5662-4E20-9FA3-5A3FCBD67CDCQ57106833-CA43DB52-F434-4BBD-AE0B-628B9E416975Q57798858-41B867AA-1E37-4856-9D3D-2A1978FF5357Q58115575-61E9D659-83AA-4B46-A2D5-2E57C04A194F
P2860
Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Detection of recurrent alterna ...... als novel signatures of cancer
@en
type
label
Detection of recurrent alterna ...... als novel signatures of cancer
@en
prefLabel
Detection of recurrent alterna ...... als novel signatures of cancer
@en
P2860
P356
P1476
Detection of recurrent alterna ...... als novel signatures of cancer
@en
P2093
Michał Zawisza
P2860
P304
P356
10.1093/NAR/GKU1392
P577
2015-01-10T00:00:00Z